Bad news?

0.0250 (0.00%)View full PRR report with
Page 1 of 1
  1. 141
    Posts

    Prima Biomed Ltd.'s (PBMD, $1.61, -$0.74, -31.34%)(PRR.AU) investigational vaccine therapy to treat a type of ovarian cancer showed no observed difference when compared with results in a control arm in an early-stage study, resulting in the Australian company temporarily suspending enrollment in another study.

  2. 118
    Posts

    Duster, currently a Day trade play thing.

Your browser is too old for TopStocks and not secure. Please update your browser